Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glycorex Transplantation ABFRA:O33 -31.05%61 PB Ratio is 2.46 as of Aug. 05, 2026, which is 40% below its 10-year median of 4.10. GuruFocus rates FRA:O33 with a GF Score™ of 61/100 and a GF Value™ of €0.14 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,228 Biotechnology companies, Glycorex Transplantation AB ranks worse than 60.67% on this metric.
Glycorex Transplantation AB stock PB Ratio (=4.25) is close to 1-year high of 4.45.
The historical rank and industry rank for Glycorex Transplantation AB's PB Ratio or its related term are showing as below:
FRA:O33'
s PB Ratio Range Over the Past 10 Years
Min: 1.42 Med: 4.1 Max: 16.92
Current: 4.15
During the past 13 years, Glycorex Transplantation AB's highest PB Ratio was 16.92. The lowest was 1.42. And the median was 4.10.
FRA:O33's PB Ratio is ranked worse than 60.67% of 1228
companies
in the Biotechnology industry
Industry Median: 2.85
vs FRA:O33: 4.15
During the past 12 months, Glycorex Transplantation AB's average Book Value Per Share Growth Rate was -20.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -24.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -22.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -5.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Glycorex Transplantation AB was 23.60% per year. The lowest was -26.40% per year. And the median was -3.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Glycorex Transplantation AB PB Ratio Related Terms
Glycorex Transplantation AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Glycorex Transplantation AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glycorex Transplantation AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Glycorex Transplantation AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Glycorex Transplantation AB (FRA:O33) has a PB Ratio of 2.46 as of Aug. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Glycorex Transplantation AB and its competitors. This is 40% below median its historical median of 4.10. Over the past decade, Glycorex Transplantation AB's PB Ratio has ranged from 1.42 to 16.92. According to the industry distribution chart, Glycorex Transplantation AB ranks #745 out of 1228 companies in the Biotechnology industry, placing it in the top 60.7%.
Is Glycorex Transplantation AB's PB Ratio too high?
Glycorex Transplantation AB's current PB Ratio of 2.46 is 40% below median its 10-year median of 4.10. Over the past 10 years, this metric has ranged from a low of 1.42 to a high of 16.92. The Biotechnology industry median PB Ratio is 2.85. Glycorex Transplantation AB's value of 2.46 is 13.7% below this industry median. Based on the distribution chart, Glycorex Transplantation AB ranks #745 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glycorex Transplantation AB ranks #745 out of 1228 companies for PB Ratio. This places Glycorex Transplantation AB in the lower half of its industry. The industry median PB Ratio is 2.85. Glycorex Transplantation AB's value of 2.46 is 13.7% below this benchmark. Historically, Glycorex Transplantation AB's own PB Ratio has ranged from 1.42 to 16.92 over the past decade. While the company's 10-year median is 4.10 vs. the industry median of 2.85, Glycorex Transplantation AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.85, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glycorex Transplantation AB's current PB Ratio of 2.46 is 13.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Glycorex Transplantation AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glycorex Transplantation AB's current PB Ratio is 2.46, which is 40% below median its own 10-year median of 4.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (FRA:O33) is currently considered Possible Value Trap. The stock's GF Value™ is €0.14, compared to a current price of €0.09 — trading 36.7% below its estimated fair value. The current PB Ratio is 2.46, which is 40% below median its 10-year median of 4.10 and 13.7% below the Biotechnology industry median of 2.85. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Glycorex Transplantation AB (FRA:O33), the current PB Ratio is 2.46 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glycorex Transplantation AB (FRA:O33) Overvalued in 2026?
Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued.
The current stock price of €0.09 is trading 36.7% below its estimated GF Value™ of €0.14.
GuruFocus considers Glycorex Transplantation AB to be Possible Value Trap.
Key valuation signals for FRA:O33:
PB Ratio: 2.46 (40% below median its 10-year median of 4.10)
GF Value™: €0.14 vs. price of €0.09 (36.7% below fair value)
Industry Position: 13.7% below the Biotechnology median (#745 of 1228)
No single metric tells the full story. See the FRA:O33 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score
Get the complete analysis for FRA:O33
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O33 has been successfully added to your 
